ReviewJournal of clinical medicine2021
ANCA-Associated Vasculitis: An Update.
Review in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
100 citing papers in PubMed, 1 synthesis or guideline pooled it, 166 citations in OpenAlex.
- Risk of intracranial hemorrhage in anti-neutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids: a systematic review of case reports.Rheumatology international · 2025Pooled it
- Efficacy and safety of avacopan in patients aged 65 years and older with ANCA-associated vasculitis: a post hoc analysis of data from the ADVOCATE trial.Rheumatology (Oxford, England) · 2025Trial
- Article
- Review
- Article
- New-Onset ANCA-Associated Vasculitis in Pregnancy Successfully Treated With Rituximab: A Case Report and Literature Review.Kidney medicine · 2026Article
- Soluble CD95L triggers Caspase-10-driven reactive oxygen species production in neutrophils and aggravates anti-neutrophil cytoplasmic antibody-vasculitis.Nature communications · 2026Article
- Article
- Concurrent anti-GBM disease and p-ANCA vasculitis presenting as pulmonary-renal syndrome in a patient with chronic kidney disease: a case report.Annals of medicine and surgery (2012) · 2026Article
- Beyond Remission: The Cardiometabolic Burden of ANCA-Associated Vasculitis.Arquivos brasileiros de cardiologia · 2026Article
- Diagnostic Performance of ANCA IIF in Relation to PR3 and MPO Antibodies: Impact of Formalin Reactivity in a Large Real-World Cohort.Diagnostics (Basel, Switzerland) · 2026Article
- Effective Management of a Rare Case of Pediatric ANCA-Associated Vasculitis With Rituximab and Mycophenolate Mofetil.The American journal of case reports · 2026Article
- Mapping a path forward: addressing disease burden, pathways and solutions in ANCA-associated vasculitis.Rheumatology (Oxford, England) · 2026Review
- Impact of Infection-Related Immune Responses on ANCA-Associated Vasculitis in Finns: A Mendelian Randomization Study.Genetics research · 2026Article
- Factors Associated With the High Prevalence of Metabolic Syndrome in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.Arquivos brasileiros de cardiologia · 2026Article
- B cell receptor signaling in autoimmune rheumatic diseases: regulatory mechanisms and therapeutic targeting.Frontiers in immunology · 2026Review
- Immune checkpoint imbalance in ANCA-associated vasculitis: insights into disease activity and precision immunotherapy.Frontiers in medicine · 2026Review
- Incidence and clinical features of ANCA-associated vasculitis before and during the COVID-19 pandemic: experience from a single-center in Northern Spain.Frontiers in medicine · 2026Article
- Understanding the burden of ANCA-associated vasculitis.Rheumatology (Oxford, England) · 2026Review
- Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Overlapping with IgG4-Related Disease Accompanied by Mesangial Immunoglobulin a Deposition: A Case Report.Journal of inflammation research · 2026Article
40 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) represents a group of small vessel vasculitides characterized by granulomatous and neutrophilic tissue inflammation, often associated with the production of antibodies that target neutrophil antigens. The two major antigens targeted by ANCAs are leukocyte proteinase 3 (PR3) and myeloperoxidase (MPO). AAV can be classified into 3 categories based on patterns of clinical involvement: namely, granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic GPA (EGPA). Clinically, AAV involves many organ systems including the lungs, kidneys, skin, and nervous system. The prognosis of AAV has improved dramatically due to advances in the understanding of its pathogenesis and treatment modalities. This review will highlight some of the recent updates in our understanding of the pathogenesis, clinical manifestations, and treatment options in patients with AAV focusing on kidney involvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.